SMT202100152T1 - Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab - Google Patents

Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Info

Publication number
SMT202100152T1
SMT202100152T1 SM20210152T SMT202100152T SMT202100152T1 SM T202100152 T1 SMT202100152 T1 SM T202100152T1 SM 20210152 T SM20210152 T SM 20210152T SM T202100152 T SMT202100152 T SM T202100152T SM T202100152 T1 SMT202100152 T1 SM T202100152T1
Authority
SM
San Marino
Prior art keywords
benralizumab
asthmatics
methods
expiratory volume
forced expiratory
Prior art date
Application number
SM20210152T
Other languages
English (en)
Italian (it)
Inventor
Bing Wang
Christine Ward
Lorin Roskos
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SMT202100152T1 publication Critical patent/SMT202100152T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
SM20210152T 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab SMT202100152T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
EP19158446.5A EP3520811B1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (1)

Publication Number Publication Date
SMT202100152T1 true SMT202100152T1 (it) 2021-05-07

Family

ID=52448838

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20210152T SMT202100152T1 (it) 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
SM20190311T SMT201900311T1 (it) 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20190311T SMT201900311T1 (it) 2013-08-12 2014-08-07 Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Country Status (26)

Country Link
US (1) US9441046B2 (enExample)
EP (4) EP3520811B1 (enExample)
JP (4) JP6746496B2 (enExample)
KR (1) KR102337599B1 (enExample)
CN (2) CN111588849A (enExample)
AU (2) AU2014306959B2 (enExample)
BR (1) BR112016002317A8 (enExample)
CA (1) CA2917603C (enExample)
CY (2) CY1122033T1 (enExample)
DK (2) DK3033104T3 (enExample)
ES (2) ES2866426T3 (enExample)
HK (1) HK1222559A1 (enExample)
HR (2) HRP20190920T1 (enExample)
HU (2) HUE043497T2 (enExample)
LT (2) LT3033104T (enExample)
ME (1) ME03403B (enExample)
MX (2) MX381102B (enExample)
PL (2) PL3033104T3 (enExample)
PT (2) PT3033104T (enExample)
RS (2) RS58711B1 (enExample)
RU (1) RU2703568C2 (enExample)
SG (1) SG11201600483QA (enExample)
SI (2) SI3033104T1 (enExample)
SM (2) SMT202100152T1 (enExample)
TR (1) TR201907907T4 (enExample)
WO (1) WO2015023507A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023504A1 (en) 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK3072525T3 (en) * 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
WO2015023504A1 (en) 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab

Also Published As

Publication number Publication date
ES2733602T3 (es) 2019-12-02
EP3033104A2 (en) 2016-06-22
RU2016108809A (ru) 2017-09-18
TR201907907T4 (tr) 2019-06-21
CN111588849A (zh) 2020-08-28
MX381102B (es) 2025-03-12
JP2022120010A (ja) 2022-08-17
LT3033104T (lt) 2019-06-25
JP6746496B2 (ja) 2020-08-26
PT3520811T (pt) 2021-03-15
JP2020125304A (ja) 2020-08-20
KR20160043049A (ko) 2016-04-20
MX2021003826A (es) 2021-05-27
HK1225300A1 (en) 2017-09-08
AU2014306959B2 (en) 2019-11-21
HUE053627T2 (hu) 2021-07-28
EP3520811A1 (en) 2019-08-07
CY1124399T1 (el) 2022-07-22
BR112016002317A2 (pt) 2017-12-12
KR102337599B1 (ko) 2021-12-10
SMT201900311T1 (it) 2019-07-11
AU2020201277A1 (en) 2020-03-12
EP4579236A3 (en) 2025-09-17
PL3033104T3 (pl) 2019-09-30
DK3520811T3 (da) 2021-03-22
HUE043497T2 (hu) 2019-08-28
US9441046B2 (en) 2016-09-13
WO2015023507A2 (en) 2015-02-19
EP3520811B1 (en) 2020-12-30
HRP20190920T1 (hr) 2019-07-12
CA2917603C (en) 2023-05-16
JP2016527325A (ja) 2016-09-08
EP4579236A2 (en) 2025-07-02
ME03403B (me) 2020-01-20
EP4636400A2 (en) 2025-10-22
EP3033104A4 (en) 2017-03-22
RU2016108809A3 (enExample) 2018-06-18
WO2015023507A3 (en) 2015-04-09
CY1122033T1 (el) 2020-10-14
EP3875487A1 (en) 2021-09-08
SG11201600483QA (en) 2016-02-26
EP3033104B1 (en) 2019-04-03
US20150044203A1 (en) 2015-02-12
WO2015023507A8 (en) 2015-09-24
CA2917603A1 (en) 2015-02-19
HK1222559A1 (zh) 2017-07-07
MX2016001384A (es) 2016-08-03
HRP20210406T1 (hr) 2021-04-30
AU2014306959A1 (en) 2016-02-04
PT3033104T (pt) 2019-06-27
BR112016002317A8 (pt) 2018-06-12
RS58711B1 (sr) 2019-06-28
RS61565B1 (sr) 2021-04-29
ES2866426T3 (es) 2021-10-19
DK3033104T3 (da) 2019-06-17
RU2703568C2 (ru) 2019-10-21
PL3520811T3 (pl) 2021-08-02
SI3033104T1 (sl) 2019-06-28
LT3520811T (lt) 2021-03-25
CN105451769A (zh) 2016-03-30
JP2024129140A (ja) 2024-09-26
SI3520811T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
IL281275B (en) Methods useful in the synthesis of helichondrin b analogs
IL245524A0 (en) New methods for the production of active tert
SMT202100152T1 (it) Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
PL2950633T3 (pl) Sposoby indukowania tolerancji na suszę w uprawach
GB201304101D0 (en) Improvements in or relating to street furniture
SG11201509450QA (en) Methods to produce particles comprising therapeutic proteins
GB201321337D0 (en) Improvements in or relating to stairlifts
GB201316208D0 (en) Improvements in or relating to optimisation techniques
GB2522975B (en) Improvements to handle assemblies
GB201310608D0 (en) Improvements in or relating to furniture
FI20135228L (fi) Monikäyttötuoli
GB201313010D0 (en) Improvements in or relating to posts
GB2518834B (en) Improvements in or relating to stairlifts
GB201308430D0 (en) Improvements in or relating to replaceable lamps
GB201322789D0 (en) Purge in model
TH1501000545A (th) ยางธรรมชาติที่มีนาโนคาร์บอน (Natural rubber containing nanocarbon)
GB201315795D0 (en) Improvements in or relating to storage
GB201315798D0 (en) Improvements in or relating to storage
GB201315797D0 (en) Improvements in or relating to storage
GB201303688D0 (en) Improvements in or relating to stairlifts
GB201306136D0 (en) Improvements in or relating to storage
GB201306134D0 (en) Improvements in or relating to storage
FI20120373L (fi) Opiskelu- ja työtuoli
FI9766U1 (fi) Tilavuudeltaan säädettävä kovakuorinen lompakko
GB201307903D0 (en) Rapid method to Diagnosis Hepatitis